KR830000899A - Herbal composition - Google Patents

Herbal composition

Info

Publication number
KR830000899A
KR830000899A KR1019790004554A KR790004554A KR830000899A KR 830000899 A KR830000899 A KR 830000899A KR 1019790004554 A KR1019790004554 A KR 1019790004554A KR 790004554 A KR790004554 A KR 790004554A KR 830000899 A KR830000899 A KR 830000899A
Authority
KR
South Korea
Prior art keywords
composition according
ether
sterol
enteric
nucleus
Prior art date
Application number
KR1019790004554A
Other languages
Korean (ko)
Other versions
KR830001642B1 (en
Inventor
프란츠 요아힘
비히 패트 루드
Original Assignee
쟝 크레머, 페터 레스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쟝 크레머, 페터 레스, 산도즈 리미티드 filed Critical 쟝 크레머, 페터 레스
Publication of KR830000899A publication Critical patent/KR830000899A/en
Application granted granted Critical
Publication of KR830001642B1 publication Critical patent/KR830001642B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음No content

Description

생약조성물Herbal composition

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음This content is subject to disclosure, so the full text is not included.

Claims (33)

조성물의 핵이 맥각알칼로이드 및 폴리알콕시알킬렌스테롤 에테르를 함유하는 경구복용을 위한 1회용 고형 장용피 조성물.Disposable solid enteric coating composition for oral administration, wherein the core of the composition contains ergot alkaloid and polyalkoxyalkylenesterol ether. 맥각알칼로이드가 다음 구조식 I 화합물인 특허청구 범위 1에 따르는 조성물.A composition according to claim 1 wherein the ergot alkaloid is a compound of the following structural formula I. 상기 구조식에서 R1은 수소 또는 할로겐이고, R2는 수소 또는 탄소수 1 내지 4의 알킬이고, R3는 이소프로필, 2급-부틸, 이소부틸 또는 벤질이고, R4는 메틸 에틸 또는 이소프로필이고, R5가 수소이고, R6가 수소 또는 메톡시이거나, R5및 R6가 같이 부가적인 결합을 이루거나, 그 혼합물이다.In the above structural formula, R 1 is hydrogen or halogen, R 2 is hydrogen or alkyl having 1 to 4 carbon atoms, R 3 is isopropyl, sec-butyl, isobutyl or benzyl, and R 4 is methyl ethyl or isopropyl , R 5 is hydrogen, R 6 is hydrogen or methoxy, R 5 and R 6 together form an additional bond, or a mixture thereof. 액각알칼로이드가 디하이드로메르고타민인 특허청구 범위 1 및 2에 따르는 조성물.A composition according to claims 1 and 2, wherein the liquid angle alkaloid is dihydromergotamine. 맥각알칼로이드가 디하이드로메르고톡신인 특허청구 범위 1 및 2에 따르는 조성물.A composition according to claims 1 and 2, wherein the ergot alkaloid is dihydromergotoxin. 맥각알칼로이그가 브로모에트고크립틴인 특허청구 범위 1 및 2에 따르는 조성물.A composition according to claims 1 and 2, wherein the ergot alkaline is bromoethgocryptin. 폴리알콕시알킬렌스테롤 에테르의 친수성-지방친화성 밸런스가 10에서 20까지인 특허청구 범위 1 내지 2의 어느 하나에 따르는 조성물.The composition according to any one of claims 1 to 2, wherein the hydrophilic-lipophilic balance of the polyalkoxyalkylenesterol ether is from 10 to 20. 폴리알콕시알킬렌스테롤 에테르의 친수성-지방친화성 밸런스가 10에서 20까지인 특허청구 범위 1 내지 5의 어느 하나에 따르는 조성물.The composition according to any one of claims 1 to 5, wherein the hydrophilic-lipophilic balance of the polyalkoxyalkylenesterol ether is from 10 to 20. 폴리알콕시알킬렌 스테롤 에테르의 친수성-지방친화성 밸랜스가 12에서 16까지인 특허청구 범위 6에 따르는 조성물.A composition according to claim 6 wherein the hydrophilic-lipophilic balance of the polyalkoxyalkylene sterol ether is from 12 to 16. 폴리알콕시알킬렌 스테롤 에테르의 스테롤 부분이 라노스테롤, 디하이드로콜레스테린 및/또는 콜레스테린인 특허청구 범위 1 내지 7의 어느 하나에 따르는 조성물.A composition according to any one of claims 1 to 7 wherein the sterol moiety of the polyalkoxyalkylene sterol ether is lanosterol, dihydrocholesterine and/or cholesterine. 폴리알콕시알킬렌 스테롤 에테르가 약 8 내지 약 75의 알킬렌 옥사이드 단위로 에테르화된 스테롤인 특허청구 범위.Claims wherein the polyalkoxyalkylene sterol ether is a sterol etherified with about 8 to about 75 alkylene oxide units. 스테롤이 약 9에서 약 30까지의 알킬렌 단위로 에테르화된 특허청구 범위 9에 따르는 조성물.A composition according to claim 9 wherein the sterol is etherified with alkylene units from about 9 to about 30. 폴리알콕시알킬렌 스테롤 에테르가 에틸렌옥사이드 또는 프로필렌 옥사이드로 에테르화된 스테롤인 특허청구 범위 1 내지 10의 어느 하나에 따르는 조성물.A composition according to any one of claims 1 to 10, wherein the polyalkoxyalkylene sterol ether is a sterol etherified with ethylene oxide or propylene oxide. 장용피 재료를 셀룰로스 에스테르 유도체, 셀룰로스에테르, 아크릴수지 또는 말레산의 공중합체 및 프탈산 유도체 가운데서 선택하는 특허청구 범위 1 내지 11의 어느 하나에 따르는 조성물.A composition according to any one of claims 1 to 11, wherein the enteric coating material is selected from a cellulose ester derivative, a cellulose ether, an acrylic resin or a copolymer of maleic acid and a phthalic acid derivative. 셀룰로스 아세테이트 프탈레이트로 장용피를 입힌 특허청구 범위 12에 따르는 조성물.A composition according to claim 12, which is enterically coated with cellulose acetate phthalate. 하이드록시프로필 메틸셀룰로스프탈레이트로 장용피를 입힌 특허청구 범위 12에 따르는 조성물.A composition according to claim 12 coated with an enteric coat with hydroxypropyl methylcellulosephthalate. 메틸아크릴산 및 메틸아크릴산을 최소한 40% 함유하는 그것의 에스테르로 장용피를 입힌 특허청구범위 12에 따르는 조성물.A composition according to claim 12, which is enterically coated with methylacrylic acid and its esters containing at least 40% methylacrylic acid. 장용피에 연화제를 함유시키는 특허청구 범위 1 내지 15의 어느 하나에 따르는 조성물.A composition according to any one of claims 1 to 15, containing an emollient in the enteric coat. 연화제가 디-n-부틸프탈레이트인 특허청구 범위 16에 따르는 조성물.A composition according to claim 16 wherein the emollient is di-n-butylphthalate. 정제, 과립, 펠리트 또는 캡슐의 형을 취하는 특허청구 범위 1 내지 17의 어느 하나에 따르는 조성물.A composition according to any one of claims 1 to 17 taking the form of tablets, granules, pellets or capsules. 추가적으로 외피층을 입힌 정제형의 특허청구 범위 18에 따르는 조성물.A composition according to claim 18 in tablet form with an additional skin layer. 맥각알칼로이드 폴리알콕시알킬렌 스테롤 에테르의 중량비가 1:1 및 1:25 사이인 특허청구 범위 1 내지 19와 어느 하나에 따르는 조성물.A composition according to any one of claims 1 to 19 and wherein the weight ratio of ergot alkaloid polyalkoxyalkylene sterol ether is between 1:1 and 1:25. 맥각알칼로이드와 폴리알콕시알킬렌 스테롤 에테르의 중량비가 1:2 및 1:8사이인 특허청구 범위 19에 따르는 조성물.A composition according to claim 19 wherein the weight ratio of ergot alkaloid and polyalkoxyalkylene sterol ether is between 1:2 and 1:8. 핵이 고형용액형인 특허청구 범위 1 내지 21의 어느 하나에 따르는 조성물.A composition according to any one of claims 1 to 21, wherein the nucleus is in a solid solution form. 핵이 고형용매로써 폴리알킬렌 글리콜, 폴리비닐피롤리든 및/또는 비닐피롤리돈 및 비닐아세테이트의 공중합체를 함유하는 특허청구범위 22에 따르는 조성물.A composition according to claim 22, wherein the nucleus contains a copolymer of polyalkylene glycol, polyvinylpyrrolidone and/or vinylpyrrolidone and vinyl acetate as a solid solvent. 핵에서 맥각알칼로이드와 폴리알콕시알킬렌 스테롤 에테르 및 고형용매의 중량비가 1:1 내지 10:0.1 내지 10인 특허청구 범위 23에 따르는 조성물.A composition according to claim 23 wherein the weight ratio of ergot alkaloid and polyalkoxyalkylene sterol ether and solid solvent in the nucleus is from 1:1 to 10:0.1 to 10. 중량비가 1:2 내지 8:0.1 내지 10인 특허청구 범위 24에 따르는 조성물.A composition according to claim 24 with a weight ratio of 1:2 to 8:0.1 to 10. 중량비가 중량비가 1:2 내지 5:0.1 내지 5인 특허청구 범위 25에 따르는 조성물.A composition according to claim 25 wherein the weight ratio is from 1:2 to 5:0.1 to 5. 핵에 안정제가 함유되는 특허청구 범위 22 내지 26의 어느 하나에 따르는 조성물.A composition according to any one of claims 22 to 26, wherein the nucleus contains a stabilizer. 산을 써서 핵의 pH를 4 내지 6으로 맞추어 안정화시킨 특허청구 범위 27에 따르는 조성물.A composition according to claim 27, stabilized by adjusting the pH of the nucleus to 4 to 6 using an acid. 맥각알칼로이드 폴리알콕시알킬렌 스테롤 에테르를 함유하는 장용피를 입힌 핵으로 특징지어지는 상기 특허청구 범위 어느 하나에 명설된 바와 같은 조성물의 제조방법.A method for preparing a composition as specified in any one of the above claims, characterized by an enteric-coated nucleus containing an ergot alkaloid polyalkoxyalkylene sterol ether. 장용피를 기지방법으로 실시한 특허청구 범위 29에 따르는 방법.A method according to claim 29 in which enteric coating was carried out by a known method. 핵을 장용피용액으로 분무한 장용피정, 장용피펠리트, 또는 장용의 과립을 위한 특허청구 범위 30에 따르는 방법.A method according to claim 30 for enteric retreat, enteric pipette, or enteric granules sprayed with an enteric coating solution of the nucleus. 핵을 분무하기 전에 25°에서 40°까지 가온하는 것을 특징으로 하는 특허청구 범위 31에 따르는 방법.A method according to claim 31, characterized in that the core is heated from 25° to 40° prior to spraying. ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.※ Note: It is disclosed according to the contents of the first application.
KR1019790004554A 1978-12-21 1979-12-20 Method for preparing oral composition of ergot alkaloids KR830001642B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH13019/78 1978-12-21
CH1301978 1978-12-21

Publications (2)

Publication Number Publication Date
KR830000899A true KR830000899A (en) 1983-04-28
KR830001642B1 KR830001642B1 (en) 1983-08-22

Family

ID=4388565

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019790004554A KR830001642B1 (en) 1978-12-21 1979-12-20 Method for preparing oral composition of ergot alkaloids

Country Status (5)

Country Link
JP (1) JPS5587718A (en)
KR (1) KR830001642B1 (en)
AR (1) AR240012A1 (en)
BE (1) BE880713A (en)
ZA (1) ZA796969B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6130534A (en) * 1984-07-23 1986-02-12 Tooa Eiyoo Kk Hydrogenated ergot-alkaloid preparation and its preparation
DE4316537A1 (en) * 1993-05-18 1994-11-24 Basf Ag Preparations in the form of solid solutions
JP4965784B2 (en) * 1999-12-03 2012-07-04 ポリケム・ソシエテ・アノニム Process for producing sustained release pharmaceutical composition of ergot alkaloid with improved bioavailability and composition thereof

Also Published As

Publication number Publication date
KR830001642B1 (en) 1983-08-22
JPS5587718A (en) 1980-07-02
BE880713A (en) 1980-06-19
JPS643846B2 (en) 1989-01-23
ZA796969B (en) 1981-07-29
AR240012A1 (en) 1990-01-31

Similar Documents

Publication Publication Date Title
KR950004886B1 (en) Process for preparing pharmaceutical formulations of acid labile substances for oral use
ES2104044T3 (en) SOFT CAPSULES COATED ENTERICAS AND METHOD FOR ITS PRODUCTION.
JPS57171428A (en) Preparation of coated solid preparation
KR890014095A (en) Release-controlled pharmaceuticals and preparation method thereof
KR880004806A (en) Spray drying acetaminophen
JPS56127322A (en) Enteric coating material composition for solid drug
NO156690C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE INHANDER DERIVATIVES.
AU531762B2 (en) Aqueous emulsion coatings composition comprising self- emulsifiable epoxy ester copolymer mixture
ES462418A1 (en) Coating ensuring a controlled release of active ingredients of biologically active compositions, particularly pharmaceutical compositions and a process for preparation of biologically active compositions ensuring controlled release of active ingredients
GB1477187A (en) Pharmaceutical and like capsules'
ATE698T1 (en) ANALGESIC 6-ACYLAMINOT ETRAHYDRO-1,3,5-TRIAZINE-2,4-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR MANUFACTURE.
ZA792283B (en) Structural analogs of natural glycerides,process for their preparation and pharmaceutical compositions thereof
KR830000899A (en) Herbal composition
NO146025C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF NEW THERAPEUTIC ACTIVE BENZAPINE DERIVATIVES
ES415624A3 (en) Pharmaceutical and diagnostic compositions
JPS5780322A (en) Cardiotonic agent
JPS52282A (en) Process for preparation of carbostyril derivatives
US4411882A (en) Galenical compositions
SE7903554L (en) NEW ISOKINOLIN DERIVATIVES, PROCEDURES FOR THE PREPARATION OF THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
JPS54128588A (en) Antidepressive drugs consisting mainly of 2-(1-piperazinyl)- 4-phenylquinoline
JPS5585515A (en) Smell preparation
JPS5712029A (en) Modification of cellulose ether film
US4223008A (en) Slow release pharmaceutical compositions containing 3-[2-(4-benzamido-1-piperidyl)ethyl]indole, embonate
JPS5484020A (en) Composition for coating medicine and method for coating the same
NL186768B (en) METHOD FOR PREPARING A PHARMACEUTICAL OR VETERINARY PREPARATION, AND METHOD FOR PREPARING THEREFOR AS USING A MEDICINAL COMPOUND 3-OXO-5,6-DIHYDRO-1,2,4-OXADIAZINES